An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention

BackgroundNeoplastic transformation is a multistep process in which distinct gene products of specific cell regulatory pathways are involved at each stage. Identification of overexpressed genes provides an unprecedented opportunity to address the immune system against antigens typical of defined stages of neoplastic transformation. HER-2/neu/ERBB2 (Her2) oncogene is a prototype of deregulated oncogenic protein kinase membrane receptors. Mice transgenic for rat Her2 (BALB-neuT mice) were studied to evaluate the stage in which vaccines can prevent the onset of Her2 driven mammary carcinomas. As Her2 is not overexpressed in all mammary carcinomas, definition of an additional set of tumor associated antigens (TAAs) expressed at defined stages by most breast carcinomas would allow a broader coverage of vaccination. To address this question, a meta-analysis was performed on two transcription profile studies [1, 2] to identify a set of new TAA targets to be used instead of or in conjunction with Her2.ResultsThe five TAAs identified (Tes, Rcn2, Rnf4, Cradd, Galnt3) are those whose expression is linearly related to the tumor mass increase in BALB-neuT mammary glands. Moreover, they have a low expression in normal tissues and are generally expressed in human breast tumors, though at a lower level than Her2.ConclusionAlthough the number of putative TAAs identified is limited, this pilot study suggests that meta-analysis of expression profiles produces results that could assist in the designing of pre-clinical immunopreventive vaccines.

[1]  S. Hedjazifar,et al.  c-erbB2-induced disruption of matrix adhesion and morphogenesis reveals a novel role for protein kinase B as a negative regulator of alpha(2)beta(1) integrin function. , 2002, Molecular biology of the cell.

[2]  Piero Musiani,et al.  Cure of Mammary Carcinomas in Her-2 Transgenic Mice through Sequential Stimulation of Innate (Neoadjuvant Interleukin-12) and Adaptive (DNA Vaccine Electroporation) Immunity , 2005, Clinical Cancer Research.

[3]  M J O'Hare,et al.  Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. , 2001, Cancer immunity.

[4]  Thomas K. Hoffmann,et al.  Identification of Cyclin B1 as a Shared Human Epithelial Tumor-Associated Antigen Recognized by T Cells , 2001, The Journal of experimental medicine.

[5]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[6]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[7]  P. Musiani,et al.  Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[8]  Piero Musiani,et al.  Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. , 2004, The Journal of clinical investigation.

[9]  Piero Musiani,et al.  Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. , 2003, The Journal of clinical investigation.

[10]  R. Xu,et al.  Amplification of Her-2/neu Gene in Her-2/neu-Overexpressing and -Nonexpressing Breast Carcinomas and Their Synchronous Benign, Premalignant, and Metastatic Lesions Detected by FISH in Archival Material , 2002, Modern Pathology.

[11]  Piero Musiani,et al.  Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. , 2004, Cancer research.

[12]  M. Brattain,et al.  Differential display of reticulocalbin in the highly invasive cell line, MDA-MB-435, versus the poorly invasive cell line, MCF-7. , 1997, Biochemical and biophysical research communications.

[13]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  O. Jänne,et al.  Coregulator Small Nuclear RING Finger Protein (SNURF) Enhances Sp1- and Steroid Receptor-mediated Transcription by Different Mechanisms* , 2000, The Journal of Biological Chemistry.

[15]  Hiroaki Nagano,et al.  Expression of Uridine Diphosphate N-Acetyl-α-D-Galactosamine: Polypeptide N-Acetylgalactosaminyl Transferase 3 in Adenocarcinoma of the Pancreas , 2003, Pathobiology.

[16]  Piero Musiani,et al.  Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario , 2005, Cancer Immunology, Immunotherapy.

[17]  Doron Lancet,et al.  Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification , 2005, Bioinform..

[18]  G. Viglietto,et al.  RNF4 is a growth inhibitor expressed in germ cells but not in human testicular tumors. , 2001, The American journal of pathology.

[19]  Thierry Boon,et al.  Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.

[20]  O. Finn,et al.  Premalignant Lesions as Targets for Cancer Vaccines , 2003, The Journal of experimental medicine.

[21]  Saija Savolainen,et al.  Small nuclear RING finger protein expression during gonad development: regulation by gonadotropins and estrogen in the postnatal ovary. , 2004, Endocrinology.

[22]  Vishva M. Dixit,et al.  RAIDD is a new 'death' adaptor molecule , 1997, Nature.

[23]  Guido Forni,et al.  Antitumor vaccines: is it possible to prevent a tumor? , 2002, Cancer Immunology, Immunotherapy.

[24]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[25]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[26]  George A Calin,et al.  Adenoviral transduction of TESTIN gene into breast and uterine cancer cell lines promotes apoptosis and tumor reduction in vivo. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  Piero Musiani,et al.  Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. , 2005, The American journal of pathology.

[28]  S. Srinivasula,et al.  CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP. , 1997, Cancer research.

[29]  Bernhard Horsthemke,et al.  The RING Finger Protein RNF4, a Co-regulator of Transcription, Interacts with the TRPS1 Transcription Factor* , 2003, Journal of Biological Chemistry.

[30]  Tatiana A. Tatusova,et al.  Entrez Gene: gene-centered information at NCBI , 2004, Nucleic Acids Res..

[31]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[32]  M J Bissell,et al.  Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. , 1998, The American journal of pathology.

[33]  Sara A Byron,et al.  Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer. , 2003, Seminars in oncology.

[34]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[35]  K. Huebner,et al.  Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer. , 2003, Genomics.

[36]  Kenichi Matsuo,et al.  Expression of UDP-N-Acetyl-α-d-Galactosamine-Polypeptide N-Acetylgalactosaminyltransferase Isozyme 3 in the Subserosal Layer Correlates with Postsurgical Survival of Pathological Tumor Stage 2 Carcinoma of the Gallbladder , 2004, Clinical Cancer Research.

[37]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Ostrand-Rosenberg,et al.  Animal models of tumor immunity, immunotherapy and cancer vaccines. , 2004, Current opinion in immunology.

[39]  Makoto Asada,et al.  Aberrant expression of integrin and erbB subunits in breast cancer cell lines. , 2002, International journal of oncology.

[40]  John Quackenbush,et al.  Open source software for the analysis of microarray data. , 2003, BioTechniques.

[41]  O. Finn,et al.  Cancer vaccines: between the idea and the reality , 2003, Nature Reviews Immunology.

[42]  P. Musiani,et al.  Immunoprevention of cancer: is the time ripe? , 2000, Cancer research.